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Pseudoexfoliation syndrome (PEXS) and glaucoma (PEXG) are assumed to be caused
by a generalized elastosis leading to the accumulation of PEX material in ocular as
well as in extraocular tissues. The exact pathophysiology of PEXS is still elusive. PEXG,
the most common type of secondary open-angle glaucoma (OAG), is characterized
by large peaks of intraocular pressure (IOP) with a progressive loss of the visual field.
Agonistic autoantibodies (agAAbs) against the β2-adrenergic receptor (AR) have been
shown to be present in sera of patients with primary and secondary OAG and ocular
hypertension and are seemingly linked to IOP. In the present study, we investigated the
autoantibodies directed against the β2-AR in sera of patients with PEXS and PEXG. We
recruited 15, 10, and 15 patients with PEXG, PEXS, and primary OAG, respectively. Ten
healthy individuals served as controls. All patients underwent standard ophthalmological
examination with Octopus G1 perimetry. agAAbs prepared from serum samples were
analyzed in a rat cardiomyocyte–based bioassay for the presence of agAAbs. We
identified the interacting loop of the β2-AR and the immunoglobulin G (IgG) subclasses
using synthetic peptides corresponding to the extracellular loops of the receptors
and enzyme-linked immunosorbent assay, respectively. None of the controls were β2-
agAAb–positive (0.2 ± 0.5 U). No β2-agAAbs (0.2 ± 0.4 U), but inhibitory β2-AAbs were
observed in 80% of the patients that partially blocked the drug-induced β2-adrenergic
stimulation; 5.8 ± 1.7 U vs. 11.1 ± 0.9 U for clenbuterol in the absence and the
presence of sera from patients with PEXS, respectively. Epitope analyses identified the
third extracellular loop of the β2-AR as the target of the inhibitory β2-AAbs, being of
IgG3 subtype in PEXS patients. In contrast, patients with PEXG showed β2-agAAbs
(5.6 ± 0.9 U), but no inhibitory ones. The β2-agAAbs levels of patients with PEXG and
primary OAG patients (3.9 ± 2.8 U; p > 0.05) were at a similar level. In two cases of
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PEXG, the β2-agAAbs exert synergistic effects with clenbuterol. The activity increased
from 11.5 ± 0.3 (clenbuterol only) to 16.3 ± 0.9 U. As autoimmune mechanisms were
reportedly involved in the pathogenesis of glaucoma, agonistic and inhibitory β2-AAbs
seem to be a part of this multifactorial interplay.
Keywords: autoantibodies, glaucoma, pseudoexfoliation, β2-adrenergic receptor, imbalanced autonomic theory
INTRODUCTION
Pseudoexfoliation syndrome (PEXS) is an age-related disorder
affecting the extracellular matrix of the whole body (Elhawy
et al., 2012; Scharfenberg and Schlotzer-Schrehardt, 2012). It is
characterized by the pathological accumulation of extracellular
material (i.e., PEX material) in intraocular and extraocular tissues
(Ritch and Schlotzer-Schrehardt, 2001; Elhawy et al., 2012).
PEX material consists of fibrillar aggregates containing elastic
fiber components such as elastin, fibrillin-1, fibulin, microfibril-
associated glycoprotein-1 (MAGP-1), latent transforming growth
factor β (LTBP)1/2, and cross-linking enzymes such as lysyl
oxidase-like 1 (LOXL1) (Schlotzer-Schrehardt et al., 2000;
Krumbiegel et al., 2009; Lee et al., 2009; Zenkel and Schlotzer-
Schrehardt, 2014; Founti et al., 2015), which can accumulate
in the trabecular meshwork, the main outflow pathway of
the eye, and may reduce the outflow of aqueous humor and
increased intraocular pressure (IOP) (Johnson and Brubaker,
1982). Consequently, PEXS is strongly associated with the
development of PEX glaucoma (PEXG) (Schlotzer-Schrehardt
et al., 2002; Anastasopoulos et al., 2015). The latter is the most
common type of secondary open-angle glaucoma (SOAG) (Ritch,
2001). The pathophysiology of PEXS and PEXG is still elusive
(Anastasopoulos et al., 2015; Schlotzer-Schrehardt and Khor,
2021). It is widely assumed that a generalized elastosis, induced
by stress, is the principal process in the pathophysiology of PEXS
(Schlotzer-Schrehardt et al., 2002; Anastasopoulos et al., 2015;
Schlotzer-Schrehardt and Khor, 2021). Transforming growth
factor β1 (TGF-β1), being increased in aqueous humor of PEXG
and PEXS, and oxidative stress were considered to be the
main contributors to the disease (Schlotzer-Schrehardt et al.,
2001; Schlotzer-Schrehardt, 2010). PEX is reportedly associated
with an increased risk of vascular diseases like myocardial
infarction, coronary artery disease, aortic aneurysms, stroke, and
cerebrovascular disease (Mitchell et al., 1997; Praveen et al.,
2011; Yokusoglu, 2012; Gonen et al., 2013; Andrikopoulos et al.,
2014; Siordia et al., 2016). Again the underlying mechanisms
are not fully understood (Mitchell et al., 1997; Siordia et al.,
2016). As with other glaucomas, the main target in treating
PEXG is the increased IOP (Schlotzer-Schrehardt et al., 2002;
Anastasopoulos et al., 2015). All conservative, laser, or surgical
strategies aim to lower IOP up to an individual target level in
order to win sighted lifetime (Lusthaus and Goldberg, 2019;
Cvenkel and Kolko, 2020). Reduction of IOP by 1 mm Hg is
known to prevent the visual field loss of patients by 10% (Leske
et al., 2003) and should be made strictly forward (Musch et al.,
2011). A main antiglaucomatous medication is timolol, a blocker
of the β2-adrenergic receptor (AR) (Katz et al., 1976; Barnes
and Moshirfar, 2021), that reduces the formation of aqueous
humor by up to 50% (Coakes and Brubaker, 1978; Yablonski
et al., 1978; Dailey et al., 1982; Topper and Brubaker, 1985;
Mccannel et al., 1992; Wayman et al., 1997; Larsson, 2001).
As β1-AR blockers (e.g., betaxolol) reportedly lower IOP less
effectively than β2-AR blockers, the role of the latter in regulating
IOP appears to be predominant (Gaul et al., 1989). β2-ARs
are expressed on cells of the ciliary body and the trabecular
meshwork, the tissues involved in aqueous humor production
and outflow (Wax and Molinoff, 1987; Crider and Sharif, 2002).
Cells of the optic nerve and retinal pericytes are further tissues
that express β2-AR (Mantyh et al., 1995; Feher et al., 2005).
agAAbs against β2-AR (β2-agAAbs) have been detected in the
sera of patients with primary open-angle glaucoma (POAG) and
SOAG, as well as ocular hypertension (OHT) (Junemann et al.,
2018; Hohberger et al., 2019a). These agAAbs were mainly of the
immunoglobulin G3 (IgG3) subtype and were directed against
the second extracellular loop of the β2-AR (peptide 181–192)
(Junemann et al., 2018). The immunological targeting of the
β2-AR is the basis for the hypothesis of an involvement of β2-
agAAbs in dysregulation of IOP (Zimmerman, 1977). The IOP
is the result of production (ciliary body) and outflow (trabecular
meshwork, uveosclera) of the aqueous humor (Johnstone et al.,
2020; Kaufman, 2020; Sunderland and Sapra, 2021). Clinical data
of patients with POAG, showing a reduced IOP after removal
of all circulating IgG antibodies by immunoadsorption, support
this hypothesis (Junemann et al., 2018). These findings indicated
a potential role for autoimmune processes in the dysregulation
of IOP. As patients with PEXG typically show an increased IOP
with large fluctuations (Heijl et al., 2009), we hypothesize a role
of the β2-agAAbs in the development of PEXG. Various types of
agAAbs, directed against the β2-AR, were described in literature
(Wallukat and Wollenberger, 1991; Wallukat, 2002; Junemann
et al., 2018): agonistic and inhibitory AAbs activate and block
the β2-AR, respectively. It was the aim of this study to analyze




Fifty subjects were recruited from the Department of
Ophthalmology, University of Erlangen-Nuremberg:
patients [n = 40; PEXG (n = 15), PEX (n = 10), POAG
(n = 15)] and controls (n = 10). All patients underwent a
complete ophthalmological examination including slit-lamp
biomicroscopy, funduscopy, and measurement of IOP by
Goldmann applanation tonometry (Haag Streit, Koeniz,
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Switzerland). In addition, we performed standard white-on-
white full-field perimetry (Octopus 500, G1 protocol; Interzeag,
Schlieren, Switzerland).
PEX Glaucoma
Diagnosis of PEXG was based on an open anterior chamber angle,
the presence of PEX material on anterior segment structures,
repeated elevated IOP > 21 mm Hg, glaucomatous alterations of
the optic disc according to Jonas’ classification (Jonas et al., 1988),
and perimetric field loss, confirmed at least once.
PEX Syndrome
Patients with PEXS showed PEX material deposits in the anterior
chamber, but without any signs of glaucoma (Scharfenberg and
Schlotzer-Schrehardt, 2012; Hohberger et al., 2019b).
POAG
Diagnosis of POAG was based on the glaucoma criteria for PEXG,
yet without any signs of PEX material on ocular structures (Jonas
et al., 1988; Barnes and Moshirfar, 2021).
Controls
Tonometry, slit-lamp inspection, funduscopy, and papillometry
were normal in control subjects. No signs of PEX or glaucoma
were observed, yet the presence of cataract was allowed.
Blood samples were collected according to clinical all-day
life procedures and centrifuged, and sera were stored at −80◦C
previous to analysis. All individuals declared informed consent.
The study was performed according to the tenets of the
Declaration of Helsinki and approved by the Ethic Committee of
the University of Erlangen and the Max-Delbrück-Centrum for
Molecular Medicine, Berlin-Buch (Y 9004/19, 02.11.2020).
Cardiomyocyte Bioassay
The cardiomyocyte bioassay was used as described previously
(Junemann et al., 2018). Cell culture of cardiac myocytes (heart
ventricle of 1–3-day-old Sprague–Dawley rats) was digested with
a 0.25% solution of crude porcine trypsin (Serva, Germany).
The cells were dispersed and suspended in SM20-I medium
(Biochrom, Germany), glutamine (Serva, Germany), which
contained streptomycin (HEFA Pharma, Germany), penicillin
(Heyl, Germany), hydrocortisone (Merck, Germany), 10%
heat-inactivated neonatal calf serum (Gibco, Germany), and
fluorodeoxyuridine (Serva, Germany). The cells were seeded
with a field density of 160,000 cells/cm2. After 24 h, the
culture medium was replaced, respectively. Before stimulation,
the cardiomyocytes were cultured for 3–4 days (37◦C). Two
hours before the experiment, the medium was renewed. After
incubation with the immunoglobulin fractions of the sera of
each proband (1:40, for 60 min), the beating rates (BRs) of the
cardiomyocytes were counted for 7–10 spontaneously beating
cells for 15 s at a heated stage inverted microscope (37◦C). One
unit reflects 4 beats/min (i.e., adrenergic activity). Samples of less
than 2 units of adrenergic activity were considered as normal.
Differentiation between agonistic and inhibitory β2-AAbs was
done after additional incubation with 3 µM clenbuterol; the
latter one partially blocked the clenbuterol effect. Application
of ICI-118,551 (2 µL ICI to 2 mL medium in order to avoid
dilution) was done for identification of the receptor type (β2-
receptor).
Preparation of the Serum
Immunoglobulins
The IgGs were prepared from sera of patients by direct
ammonium sulfate precipitation (final concentration of 40%)
overnight at 4◦C. Afterward, the precipitates were centrifuged
(4,000 × g, 30 min). The pellets were dissolved in dialysis buffer
(154 mmol/L NaCl, 10 mmol/L Na2HPO4/NaH2PO4, pH 7.2).
Precipitating, washing, and dissolving were repeated twice. The
samples were dialyzed against phosphate-buffered saline (4◦C,
3 days) prior to application to the cardiomyocyte bioassay. The
samples were stored at –20◦C.
Characterization of the Target Loop of
Inhibitory AAbs Against β2-AR
Characterization of the target loop was done as described
previously (Junemann et al., 2018). Synthetic peptides
corresponding to the extracellular loops I, II, and III of the
human β2-AR were used to identify the molecular domain of the
inhibitory β2-AAbs:
1. loop I (HILMKMWTFGNFWCEFWT).
2. loop II (HWYRATHQEAINCYANETCCDFFTNQ).
3. loop III (VIQDNLIRKEV).
After shaking 0.5 µg peptide in 50 µL IgG fraction, they were
incubated for 1 h at room temperature before adding them to the
bioassay (final IgG dilution of 1:40).
Analysis of IgG Subclass of the Inhibitory
AAbs Against β2-AR
IgG subclass analysis of the inhibitory AAbs was done as
described previously (Junemann et al., 2018). IgGs (50 µL)
from selected patients were treated with murine monoclonal
anti-human IgG1, IgG2, IgG3, and IgG4 antibodies (3 µL,
SEROTEC, Germany). After incubation (1 h, room temperature),
each sample was treated with 3 µL of a polyclonal anti-mouse
Fc antibodies (1 h) in order to increase the immune complex.
Centrifugation of the samples (at 10,000 g) was done, and the
supernatants were added to the cardiomyocyte bioassay (see
above; dilution of 1:40).
Statistical Analysis
Statistical calculations were done with Microsoft Excel 2016
and the GraphPad Prism Software version 8.3. Data are shown
as means and standard errors of the mean for each group.
The Kolmogorov–Smirnov test was run prior to analysis for
testing the normal distribution. According to this, the one-
way analysis of variance (normally distributed data) and the
Kruskal–Wallis test (non–normally distributed data) with a post-
test for multiple comparisons were applied, respectively. When
only two groups were compared, the Mann–Whitney test or
the Student’s t-test was applied, accordingly. p < 0.05 was
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POAG Primary open-angle glaucoma




β2-AAbs Autoantibody against the adrenergic β2-adrenoreceptor






LTBP Latent transforming growth factor β






considered significant. A list of all abbreviations can be seen in
Table 1.
RESULTS
We analyzed the sera of patients with PEXS and PEXG and
controls for the presence of agonistic and inhibitory AAbs
directed against the β2-AR. None of the control samples showed
a β2-agAAb seropositivity (neither agonistic nor inhibitory) of
0.2 ± 0.5 U in the cardiomyocyte bioassay. The cutoff was set at
mean ± 3 standard deviation of the controls (1.66 U).
Sera of Patients With PEXS Contain
Inhibitory but No Agonistic β2-AAbs
None of the 10 patients with PEXS showed β2-agAAbs
(mean = 0.2 ± 0.1 U) (Figure 1). Clenbuterol alone increased
the BR value of the cardiomyocytes by 11.1 ± 0.5 U. After
coincubation of the IgG with 3 µM clenbuterol (mean), a
decreased BR value was observed in 8 (80%) of 10 PEXS patients
(5.8 ± 0.6 U, p < 0.001). This decrease was attributed to the
inhibitory β2-AAbs that partially blocked the clenbuterol effect
(p< 0.001; Figure 2).
The Inhibitory β2-AAbs Recognize the
Third Extracellular Loop of the β2-AR
Clenbuterol yielded an increase in the BR (mean = 12.4 ± 0.2 U).
We performed the epitope analyses employing specific
competitive inhibitory peptides of the second and third
extracellular loops of the β2-AR (Figure 3). Loop III but not
loop II peptides neutralized the inhibitory β2-AAbs. These data
indicate that inhibitory β2-AAbs in the sera of patients with PEXS
are directed against the third extracellular loop of the β 2-AR.
FIGURE 1 | Adrenergic activity of β2-AAbs in sera of patients with PEX
syndrome (PEXS), PEX glaucoma (PEXG), and controls. Beating heart cell
rates were shown for each group [absolute data, mean ± standard deviation
(SD)]: controls, patients with PEXG and PEXS. One unit (U) reflects
4 beats/min. The values represent the adrenergic activity of β2-Abs. Samples
less than 2 units of adrenergic activity were considered as normal. Increased
beating heart cell rate was to be observed for patients with PEXG (red) when
compared to patients with PEXS and controls as measured by rat
cardiomyocyte beating heart cell rates.
FIGURE 2 | β2-AAbs in patients with PEXS are of inhibitory nature. Beating
heart cell rates after single application of sera of patients with PEXS without
(green) and with additional clenbuterol (CB, pink); reference: single incubation
with CB (blue); 1 unit (U) reflects 4 beats/min; mean ± standard deviation
(SD). β2-AAbs inhibit the increased beating heart cell rate, due to the effect of
clenbuterol, and are thus of inhibitory nature. *p < 0.001, with a post-test for
multiple comparisons.
The Inhibitory β2-AAbs Are of IgG3
Subclass
The analyses of the IgG subtype were performed by immune
precipitation with antibodies against the immunoglobulins
IgG1–4. The residual inhibitory β2-AAb activities after
preincubation with IgG subclass–specific antibodies were
4.3 ± 0.3 U (IgG1), 4.1 ± 0.2 U (IgG2), 11.7 ± 0.4 U (IgG3), and
4.0 ± 0.3 U (IgG4), respectively. The activity of the inhibitory
β2-AAbs was eliminated by preincubation with anti-IgG3
antibodies. Thus, the inhibitory β2-AAbs are of the IgG3
subclass (Figure 4).
Sera of Patients With PEXG Contain
Agonistic, Yet No Inhibitory β2-AAbs
In contrast to patients with PEXS and controls, 12 (80%) of 15 of
those with PEXG had β2-agAAbs. The mean was 4.55 ± 0.6 U
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FIGURE 3 | Epitope mapping of the inhibitory anti–β2-AAb in patients with
PEX syndrome revealed that inhibitory anti–β2-AAb targets extracellular loop
III. Peptides of the β2-adrenergic receptor extracellular loops II and III were
used for epitope mapping of the inhibitory anti–β2-AAb in patients with PEX
syndrome in the presence of clenbuterol (Cb): peptides against the third loop
did block the binding site of the inhibitory anti–β2-AAb. Consequently,
additional application of Cb did show an increase in the beating rate (orange);
peptides against the second loop did not block the binding site of the
inhibitory anti–β2-AAb. Consequently, the inhibitory nature of the inhibitory
anti–β2-AAb reduced significantly the Cb effect (∗p = 0.001, green);
application of clenbuterol alone (control, blue); 1 unit (U) reflects 4 beats/min;
mean ± standard deviation (SD).
FIGURE 4 | Identification of the IgG3 subclass of the inhibitory anti–β2-AAbs
in patients with PEX syndrome (PEXS). IgG subclass analysis was done by
IgG, prepared from sera of patients with PEXS by direct ammonium sulfate
precipitation. The samples were treated with murine monoclonal anti-human
IgG1, IgG2, IgG3, and IgG4 antibodies prior to application to the
cardiomyocyte bioassay. Beating heart cell rates after immune precipitation of
IgG1 (red), IgG2 (dark orange), IgG3 (green), and IgG4 (blue) in the presence
of additional application of clenbuterol (Cb); absolute date, mean ± standard
deviation (SD); 1 unit (U) reflects 4 beats/min. Only immune precipitation of
IgG3 removed the inhibitory effect of inhibitory anti–β2-AAbs on the Cb effect.
Consequently, the inhibitory anti–β2-AAbs are of IgG3 subtype.
in all the PEXG patients (Figure 5). The BR between patients
with PEXG and those with POAG did not differ (3.9 ± 0.7 U;
p> 0.05). In contrast, no inhibitory β2-AAbs were to be observed.
Figure 6 shows that 2 (13.3%) of the 15 of the patients with
PEXG showed synergistic β2-AAbs that markedly increased BR
values after coincubation with 1 µM clenbuterol (16.3 ± 0.6 U vs.
11.5 ± 0.1 U for clenbuterol alone). Only 1 (6.7%) of 15 PEXG
patients showed neither agonistic nor inhibitory β 2-AAbs.
Analysis of IgG subclasses showed that the β2-agAAbs
were of the IgG3 subclass (Figure 7), as only precipitation
with IgG3 antibodies eliminated the increase in the BR value
(0.29 ± 0.1 U). Consistently, no alterations of the BR were seen
after precipitation of IgG1 (5.0 ± 0.3 U), IgG2 (5.0 ± 0.5 U), and
IgG4 (5.1 ± 0.5 U). Epitope analyses of β2-AR showed that the
β2-agAAbs were directed against the second extracellular loop of
this G-protein–coupled receptor (in full) as described previously
(Junemann et al., 2018).
DISCUSSION
PEXS and PEXG are age-related ocular and systemic diseases
associated with the accumulation of abnormal fibrillar material
in intraocular and extraocular tissues (Elhawy et al., 2012;
Scharfenberg and Schlotzer-Schrehardt, 2012; Schlotzer-
Schrehardt and Khor, 2020). With an annual incidence of
1.81%, PEXS is a common condition (Astrom et al., 2007), yet
its prevalence varies worldwide (Cashwell and Shields, 1988;
Krishnadas et al., 2003; Topouzis et al., 2019). It accounts
for 25% and up to 70% of all open-angle glaucoma (OAG),
depending on the country (Ritch, 1994; Mitchell et al., 1999;
Andrikopoulos et al., 2009). Although PEXS is a major risk
factor for glaucoma, it is important to note that only 30–40
of all individuals with PEXS will develop PEXG (Thorleifsson
et al., 2007). In longitudinal population-based studies, the
probability to develop glaucoma after 10–12 years was found
to be 9–15% (Jeng et al., 2007; Topouzis et al., 2019). PEXG
is a hypertensive type of glaucoma associated with high levels
and fluctuations of the IOP, as well as an increased outflow
resistance (Kozobolis et al., 2012; Huchzermeyer et al., 2015).
Eyes of patients with PEXS tend to have higher IOP levels as
healthy eyes but can be normotensive as well (Koz et al., 2009).
Although PEXS is an established risk factor for PEXG (Mitchell
et al., 1999; Topouzis et al., 2011), the exact relationship between
the two conditions is not well understood (Topouzis et al., 2019).
Similarly, it remains unclear why only a proportion of PEXS
patients develop glaucoma, whereas the majority of them will
not (Anastasopoulos et al., 2015; Schlotzer-Schrehardt and Khor,
2021). In a longitudinal population-based study, statistically
significant risk factors for the development of PEXG among
PEXS patients included higher levels of IOP, with 26% increased
risk per mm Hg, and a history of heart attack (Topouzis et al.,
2019). It is also conceivable that an underlying defect in the
flow dynamics of the aqueous humor or additional involvement
of glaucoma susceptibility genes may predispose to glaucoma
development in PEXS eyes (Schlotzer-Schrehardt and Naumann,
1995; Kozobolis et al., 2012; Founti et al., 2015; Huchzermeyer
et al., 2015; Schlotzer-Schrehardt and Khor, 2021). It has been
suggested that in addition to IOP, further factors contribute
to the development of glaucoma in patients with PEXS. These
include genetic, epigenetic, environmental, and tissue factors
such as increased susceptibility of the lamina cribrosa to
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FIGURE 5 | Agonistic β2-agAAbs in sera of open-angle glaucoma. (A) Beating heart cell rates after incubation with sera of patients with primary open-angle
glaucoma (POAG, red) and PEX glaucoma (PEXG, orange); mean ± standard deviation (SD); 1 unit (U) reflects 4 beats/min. An increase of the beating heart cell rate
was observed in POAG and PEXG, showing its agonistic effect. Beating heart cell rate of POAG and PEXG did not differ significantly (p > 0.05). (B) Beating heart cell
rates after application of sera without (green) and with ICI-118,551 (black): the agonistic effect of the β2-AAbs is shown. The agonistic nature of β2-agAAbs activated
the receptor with consequent increase of the beating heart cell rate. These agonistic β2-agAAbs were observed in sera of patients with open-angle glaucoma.
FIGURE 6 | Synergistic β2-AAbs enhanced the effect of Cb alone and
enhanced the agonistic effect of β2-agAAbs. Beating cell rates after
incubation of live rat cardiomyocyte cells with patient sera from PEX glaucoma
(PEXG): sera without (orange) and with the β2-blocker ICI-118,551
(gray–green); synergistic β2-AAbs (red) after coincubation of the beating heart
cells with clenbuterol (Cb); reference: beating heart cell rate after incubation
with clenbuterol alone (blue) and of control subjects (green). One unit (U)
reflects 4 beats/min. Sera of PEX glaucoma showed synergistic and agonistic
β2-AAbs: agonistic β2-AAbs were present as beating heart cell rates were
increased compared to controls, reaching Cb effect alone. Synergistic
β2-AAbs enhanced the effect of Cb alone and enhanced the agonistic effect
of β2-agAAbs. ICI blocked the effect of the β2-adrenergic receptor AAbs
demonstrating the specificity for the β2-adrenergic receptor on the beating
heart cells.
optic nerve damage (Topouzis et al., 2011; Braunsmann et al.,
2012; Hohberger et al., 2018; Schlotzer-Schrehardt and Khor,
2021). Autoimmune mechanisms have also been suggested
to participate. Interestingly, there was no difference between
the antibody patterns in the aqueous humor of patients with
POAG and PEXG. This indicates common pathomechanisms
in dysregulation of aqueous humor dynamics and IOP in these
glaucoma subtypes (Joachim et al., 2007). Previously, we have
identified specific agAAbs affecting the β2-AR in sera of patients
with PEXG, as has been also shown for patients with POAG
(Hohberger et al., 2019a). A subsequent study showed that
β2-agAAbs were also present in aqueous humor samples of
patients with POAG or PEXG (Hohberger et al., 2020). It has
been hypothesized that via an impaired blood-aqueous barrier
in PEXS/PEXG, serum proteins including β2-agAAbs enter the
anterior chamber, as observed in a previous study (Schlotzer-
Schrehardt and Naumann, 2006). Alternatively, the β2-agAAbs
may be produced locally in ocular tissues. As the β2-agAAbs
already occur in very early stages of glaucoma and OHT [e.g.,
patients without optic disc alterations, yet increased IOP (OHT)]
(Junemann et al., 2018), we were interested to find out if patients
with risk of PEXG (e.g., PEXS) harbor β2-agAAbs. The findings
of the present study showed that patients with PEXS lacked any
agAAbs. Instead, 80% contained inhibitory β2-AAbs of the IgG3
subtype, which is directed against the third extracellular loop of
the β2-AR. In contrast, patients with PEXG had β2-agAAbs, yet
no inhibitory ones. Interestingly, synergistic β2-agAAbs were to
be observed in the sera of two patients with PEXG, overtopping
the effect of the β2-adrenergic agonist clenbuterol. The presence
of synergistic β2-AAbs had never been published before. The
data of the present study suggest that inhibitory AAbs present
in the majority of PEXS patients may contribute to maintenance
of normal IOP by reducing aqueous humor production and
counterbalance the age-related decline in outflow facility. In
addition, we hypothesized that agAAbs may contribute to an
increase in IOP by stimulating aqueous humor production in
the presence of increased outflow resistance due to abnormal
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FIGURE 7 | Identification of IgG3 subclass of β2-agAAbs from patients with
PEX glaucoma. Beating heart cell rates after incubation pretreated with
anti-human IgG1 (red), IgG2 (green), IgG3 (dark orange), and IgG4 (blue);
absolute date, mean ± standard deviation (SD); 1 unit (U) reflects 4 beats/min.
The increase in the beating heart cell rate was eliminated only after incubation
with anti-human IgG3 (dark orange). Only peptides against IgG3 inhibited the
agonistic nature of β2-agAAbs, visualized by the increase of the beating heart
cell rate. Consequently, the agonistic β2-agAAbs are of the IgG3 subtype.
deposits in the trabecular meshwork. This scenario potentially
contributes to the etiopathogenesis of glaucoma.
Immune and autoimmune factors were recently reported
to be involved in the pathogenesis of OAG (Tezel et al.,
2007; Tezel and Fourth ARVO/Pfizer Ophthalmics Research
Institute Conference Working Group, 2009; Joachim et al.,
2013; Rieck, 2013; Kamat et al., 2016; Von Thun Und
Hohenstein-Blaul et al., 2016; Chen et al., 2018; Hohberger
et al., 2019a; Tsai et al., 2019). A spectrum of various
autoantibodies, mostly directed against retinal antigens, has
previously been detected in the sera of patients with PEXS
and PEXG (Dervan et al., 2010; Altintas et al., 2012; Huflejt
et al., 2014; Mazeikaite et al., 2016) and in the aqueous
humor of patients with PEXG (Joachim et al., 2007). In the
latter study, there were no significant differences in these
antibody patterns between PEXG and POAG. β2-AgAAbs
levels of PEXG and POAG were similar as well. The present
study showed for the first time inhibitory β2-AAbs in the
sera of patients with PEXS. Inhibitory β2-AAbs block the
function of the β2-AR. This finding is supported by the clinical
feature of a less pronounced mydriasis after application of
10% phenylephrine in PEXS eyes compared to eyes without
PEXS (Puska, 2002). As reported in a previous study, the
local level of β2-agAAbs in the aqueous humor was increased
compared to the systemic levels (Hohberger et al., 2020).
Thus, we propose that adrenergic β2-AAbs can be locally
produced in ocular tissues. The adrenergic agAAbs in aqueous
humor are the basis of our hypothesis of inhibitory β2-
AAbs in PEXS: due to blocking of β2-AR by inhibitory β2-
AAbs, endogenous catecholamine will shift to alternative AR.
Consecutively, AR receptors will be uncoupled (acute response),
phosphorylated, and internalized (desensitization of AR) (see
Wallukat, 2002). Application of phenylephrine induces mydriasis
by contraction of the iris dilatator in unaffected eyes. This
mydriatic effect might be reduced in cells of the iris dilatator with
desensitized AR.
The exact etiopathogeneses of PEXS and PEXG are still under
debate. Two main questions remain unanswered: what is the
pathomechanism behind the unilateral clinical manifestation
of PEXS/PEXG? And why does only a subgroup of the eyes
with PEXS convert to PEXG? It is assumed that the basis
of PEXS is a genetic predisposition (e.g., LOXL1). In order
to present the clinical features with PEX material on ocular
structures, several endogenous and/or exogenous factors are
engaged in this complex interplay. Inhibitory, agonistic, and
even synergistic β2-AAbs turned out to be a common feature
in PEXS/PEXG patients in samples of the present cohort (80%);
thus, we propose that this form of autoimmunity contributes to
the clinical characteristics of PEXS/PEXG. Patients with PEXS
show inflammatory markers in their sera (Gonzalez-Iglesias
et al., 2014) and aqueous humors [e.g., interleukin (IL-6), IL-8]
TABLE 2 | Autoantibodies targeting the adrenergic β2-AR in glaucoma suspects and patients with glaucoma: pseudoexfoliation syndrome (PEXS), pseudoexfoliation
glaucoma (PEXG), ocular hypertension (OHT), primary open-angle glaucoma (POAG), secondary open-angle glaucoma (SOAG), and pigment dispersion (PD).







PEXS − − − Inhibitory β2-AAbs Present study
PEXG + + + Agonistic β2-AAbs Hohberger et al., 2019a
Agonistic β2-AAbs Hohberger et al., 2020
Synergistic β2-AAbs Present study
OHT + − − Agonistic β2-AAbs Junemann et al., 2018;
Hohberger et al., 2019a
Preperimetric POAG + − + Agonistic β2-AAbs Hohberger et al., 2019a
POAG + + + Agonistic β2-AAbs Junemann et al., 2018
Agonistic β2-AAbs Hohberger et al., 2020
SOAG due to PD + + + Agonistic β2-AAbs Hohberger et al., 2019a
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(Koliakos et al., 2001; Zenkel et al., 2010; Borras, 2018), arguing
for an underlying subclinical inflammation. According to
the findings of the present study, we propose that because
of this inflammatory status, autoimmune mechanisms occur
with the generation of autoantibodies, being inhibitory
(PEXS), agonistic, or synergistic (PEXG). The specific
adrenergic agAAbs might further increase the variation of
each clinical entity. Inhibition or overstimulation of the
AR might result in a dysregulation of the homeostatic
adrenergic balance. This non-canonical receptor–immune
complex interaction inhibits or overactivates the adenylate
cyclase, causes receptor internalization (due to overstimulation
by β2-agAAbs), or even enhances AR expression in the
sarcolemma membrane (e.g., due to inhibition by inhibitory
β2-AAbs) (Wallukat et al., 2002). If this molecular dysbalance
has sufficient “power,” clinical features might occur in
patients with PEXS/PEXG (imbalanced autonomic theory; see
Szentiványi, 1968).
Inhibitory β2-AAbs were observed in sera of patients with
allergic bronchial asthma for the first time (Wallukat and
Wollenberger, 1991). The present study showed inhibitory
β2-AAbs in patients with PEXS as second clinical entity
for the first time. Inhibitory β2-AAbs bind to β2-AR in a
competitive way (Wallukat and Wollenberger, 1991). Thus,
their binding site to the third loop seems to be different
from the β2-agAAbs that bound to the first or second
extracellular loop of the receptors. After binding, the AR
function will be blocked, reducing the activity of adenylate
cyclase with consecutive enzymatic dysbalance (Wallukat,
2002; Johnson, 2006). On the contrary, agonistic and even
synergistic β2-AAbs were present in patients with PEXG.
As described in previous studies, we propose that β2-
agAAbs contribute to the increased IOP in patients with
OAG (Junemann et al., 2018; Hohberger et al., 2019a). The
presence of synergistic β2-AAbs in sera of patients with
PEXG argues for the distinct IOP pattern in these eyes.
IOP in PEXG is elevated as in all OAG eyes, yet with
strongly enhanced diurnal fluctuations and worsened disease
progression compared to POAG. This theory might be parallel
to the “β-adrenergic theory of the atopic abnormality in
bronchial asthma” (Szentiványi, 1968). Szentiványi (1968)
hypothesized that decreased β-adrenergic sensitivity results
in an autonomic dysbalance, featuring the typical clinical
characteristics of asthma. Szentivanyi postulated that “its
ubiquitous character suggests, therefore, that the ultimate clinical
manifestation of the fundamentally same atopic abnormality
will be determined by the type of cell primarily involved,
that is, by the specialized cell system of the multicellular
organism which harbors primarily the postulated enzymatic
abnormality.” It would be of interest, if these autoimmune
phenomena will change during disease progression: if either
one agAAb subtype will disappear and another one appears,
or the presence of a specific adrenergic agAAb subtype would
potentially influence the clinical characteristics: PEXS (inhibitory
β2-AAbs) or entities with increased IOP [OAG including
PEXG and POAG (Hohberger et al., 2019a, 2020) and OHT
(Junemann et al., 2018); β2-agAAbs, Table 2]. A longitudinal
follow-up study would be of interest to focus on the pattern
of adrenergic AAbs in progressive glaucoma patients. This
offers the potential function of β2-AAbs as novel biomarkers,
supporting diagnosis and monitoring of PEXS, PEXG, and
POAG. It potentially provides novel therapeutic targets for
one of the most serious types of glaucoma (PEXG), as well
as the most common glaucoma form (POAG). The data
of the present study already enable the use of adrenergic
autoantibodies as novel biomarker, differentiating between
PEXS and PEXG. Analysis of a potential presence of adrenergic
AAbs locally in aqueous humor of PEXS and PEXG would
give additional novel hints insight toward locus of production
and pathogenesis.
CONCLUSION
The presence of inhibitory, agonistic, and even synergistic β2-
AAbs in sera of PEXS and PEXG, respectively, argues for
an imbalanced adrenergic control of the IOP (imbalanced
autonomic theory). Each adrenergic agAAb subtype might
contribute to the typical clinical characteristics (PEXS, PEXG).
Whereas patients with PEXS showed inhibitory β2-AAbs, none
of these AAbs were to be observed in the sera of PEXG, yielding
agonistic and synergistic β2-AAbs. These observations argue for
an involvement of the β2-AAbs early in the pathogenesis of
glaucoma. In addition, β2-AAbs might offer a novel option as
biomarker or therapeutic target in glaucoma.
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